# Chiome Bioscience Inc.: business model and financials

> Latest period: FY ending Dec 2025, non-consolidated, J-GAAP
> Unit: JPY millions
> Sources: 有価証券報告書－第22期(2025/01/01－2025/12/31) (S100XUJT)
> Page: https://vizora.meequs.com/en/company/chiome-bioscience
> Retrieved: 2026-09-30T20:17:50.091Z

## Company

Chiome Bioscience, founded in 2005, is a company in CRO & Clinical Testing listed on TSE Growth. It has 49 employees (consolidated).

| Field | Value |
| --- | ---: |
| Legal name | Chiome Bioscience Inc. |
| Ticker | 4583 |
| Stock price | View on Yahoo Finance (https://finance.yahoo.co.jp/quote/4583.T) |
| Listing | TSE Growth |
| Head office | 東京都渋谷区本町三丁目12番1号 |
| Representative (per filing) | 代表取締役社長 小池 正道 |
| Founded | Feb 2005 |
| Share capital | ¥1.09B |
| Employees (consolidated) | 49 |
| Average salary (parent only) | ¥7.7M |
| Fiscal year end | December |
| Website | www.chiome.co.jp (https://www.chiome.co.jp/) |
| Corporate number | 6011101054960 |
| EDINET | E26096 |
| Industries (Vizora) | CRO & Clinical Testing, Biotech & Regenerative Medicine |

> Profile source: annual securities report (S100XUJT, filed 2026-03-27). As of filing

## Key points (generated from figures)

- Chiome Bioscience brought in ¥593.3M in revenue.
- It lost about ¥165 for every ¥100 of sales at the operating level.
- Revenue changed -24.0% from the prior year.

## Key figures at a glance

| Metric | Value | Note |
| --- | ---: | ---: |
| Revenue | ¥593.3M |  |
| Operating income | -¥979.8M | Margin -165.1% |
| Net income | -¥982.8M | Margin -165.6% |
| Free cash flow | -¥976.1M |  |
| Largest business | Drug Discovery Support | of segment revenue 100.0% |
| Employees (consolidated) | 49 |  |
| EPS | ¥-14.47 |  |
| Book value per share | ¥16.18 |  |
| Equity ratio | 64.1% |  |
| Shares outstanding | 68,453,800 |  |
| Treasury shares | 12,100 |  |
| Shareholders | 24,103 |  |
| Average salary (parent only) | ¥7.7M | Filing company only |
| Cash ratio | 69.8% | Cash ÷ revenue 203.1% |
| Vs. industry median margin | -170.6 pp | CRO & Clinical Testing |
| ROA | -46.8% | Derived from disclosed figures |

## Notable figures

- FY2025, operating loss is 165 per ¥100 of revenue
- FY2025, one segment accounts for 100% of positive segment profit
- FY2025, cash is 70% of total assets

## What changed in 5 years

| Metric | FY ending Dec 2020 | FY ending Dec 2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | ¥480853000 | ¥593290000 | +23.4% |
| Operating income | ¥-1283622000 | ¥-979774000 | — |
| Operating margin | -266.9% | -165.1% | +101.8 pp |
| Employees | 42 people | 49 people | +16.7% |
| Cash and equivalents | ¥2686318000 | ¥1205026000 | -55.1% |

### Change in segment revenue mix

Span: FY ending Dec 2020 → FY ending Dec 2025. Stable segment keys are connected; unmatched shares are marked as new or reorganized. Shares use total segment revenue.

| Flow | Revenue share |
| --- | ---: |
| 創薬事業 → 事業再編・廃止 | 0.7% |
| 創薬支援事業 → 創薬支援事業 | 99.3% |
| 新設・再編 → 創薬支援事業 | 0.7% |

Segment revenue source references: 3 (derived)

## Income statement（FY ending Dec 2025, non-consolidated, J-GAAP）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Revenue | 593 | 100.0% | S100XUJT |
| Cost of revenue | 238 | 40.1% | S100XUJT |
| Gross profit | 356 | 59.9% | S100XUJT |
| SG&A | 1,335 | 225.1% | S100XUJT |
| Operating income | -980 | -165.1% | S100XUJT |
| Ordinary income | -989 | -166.7% | S100XUJT |
| Pretax income | -980 | -165.1% | S100XUJT |
| Income tax | 3 | 0.5% | S100XUJT |
| Net income | -983 | -165.6% | S100XUJT |

## Per ¥100 of revenue（FY ending Dec 2025）

| Part | JPY |
| --- | ---: |
| Cost of revenue | 40 |
| SG&A | 225 |
| Operating income | -165 |
| (Ref.) Net income | -166 |

### Margin funnel

Gross margin 59.9% → Operating margin -165.1% → Net margin -165.6%
Derived from reported figures (DERIVED).

## Year over year（FY ending Dec 2024 → FY ending Dec 2025、JPY mn）

| Metric | Prior | Current | Change | % change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 781 | 593 | -188 | -24.0% |
| Gross profit | 433 | 356 | -77 | -17.9% |
| Operating income | -1,031 | -980 | 51 | — |
| Operating cash flow | -1,001 | -936 | 65 | — |

## History（JPY mn）

| Period | Revenue | Op. income | Op. margin | Net income | Op. CF | FCF | Source |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| FY ending Dec 2019 | 448 | -1,402 | -313.2% | -1,404 | -1,537 | — | S100L137 |
| FY ending Dec 2020 | 481 | -1,284 | -266.9% | -1,294 | -1,360 | — | S100NQ6T |
| FY ending Dec 2021 | 713 | -1,334 | -187.2% | -1,480 | -1,131 | — | S100QGF6 |
| FY ending Dec 2022 | 631 | -1,259 | -199.5% | -1,243 | -1,191 | — | S100USPT |
| FY ending Dec 2023 | 682 | -1,205 | -176.6% | -1,220 | -1,069 | — | S100VI6N |
| FY ending Dec 2024 | 781 | -1,031 | -132.0% | -1,021 | -1,001 | — | S100XUJT |
| FY ending Dec 2025 | 593 | -980 | -165.1% | -983 | -936 | -976 | S100XUJT |

## People and productivity（FY ending Dec 2025, non-consolidated, J-GAAP）

| Metric | Value |
| --- | ---: |
| Revenue per employee (consolidated) | ¥12.1M |
| Operating income per employee (consolidated) | -¥20M |
| Net income per employee (consolidated) | -¥20.1M |

Employees, revenue and profit are consolidated. Average annual salary is a separate parent-company figure. Calculated from disclosed figures (DERIVED).

| History | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Employees (consolidated) | 49 | 49 | 51 | 47 | 49 |
| Average salary (parent company) | ¥7.5M | ¥7.3M | ¥6.9M | ¥7.4M | ¥7.7M |
| Average age (parent company) | 43.2 years | 44.3 years | 44.6 years | 44.8 years | 45.8 years |
| Average tenure (parent company) | 5.0 years | 5.9 years | 5.9 years | 6.1 years | 6.3 years |

Year over year: Employees (consolidated) +4.3% · Revenue (consolidated) -24.0%

## Segments（FY ending Dec 2025, non-consolidated, J-GAAP、JPY mn）

| Segment | Revenue | Share | Op. income | Op. margin |
| --- | ---: | ---: | ---: | ---: |
| Drug Discovery and Development | — | 0.0% | -777 | — |
| Drug Discovery Support | 593 | 100.0% | 356 | 59.9% |

### segmentMix — Revenue and profit mix

Calculated from disclosed figures (DERIVED). Shares use total segment revenue and total positive segment profit respectively. Difference = profit share − revenue share (pt). Inter-segment sales may prevent reconciliation to company revenue.

| Segment | Profit share | Margin |
| --- | ---: | ---: |
| Drug Discovery and Development | — | — |
| Drug Discovery Support | 100.0% | 59.9% |

Loss-making segment (excluded from profit shares): Drug Discovery and Development -777 JPY mn

Segment → industry: Drug Discovery Support → CRO & Clinical Testing / Drug Discovery and Development → Biotech & Regenerative Medicine

## Revenue by geography

No geographic revenue breakdown was disclosed.

## Cash flow（FY ending Dec 2025, non-consolidated, J-GAAP）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Operating cash flow | -936 | -157.8% | S100XUJT |
| Capital expenditure | 40 | 6.8% | S100XUJT |
| Free cash flow | -976 | -164.5% | 算出 |
| Investing cash flow | -55 | -9.3% | S100XUJT |
| Financing cash flow | 133 | 22.5% | S100XUJT |
| Change in cash | -858 | -144.7% | S100XUJT |
| Cash and equivalents | 1,205 | 203.1% | S100XUJT |

## Balance sheet

Figures are as of each fiscal year end. Derived values are marked as such in the source column. Lease liabilities are excluded from interest-bearing debt.

| Metric | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 | Source |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | 1,791 | 1,727 | 1,326 | 2,063 | 1,205 | S100USPT, S100VI6N, S100XUJT |
| Total assets | 2,339 | 2,215 | 1,751 | 2,469 | 1,728 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Net assets | 1,893 | 1,791 | 1,158 | 1,920 | 1,122 | S100USPT, S100VI6N, S100XUJT |
| Share capital | 1,516 | 2,097 | 2,388 | 996 | 1,086 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Inventories | 59 | 71 | 64 | 46 | 49 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Property, plant and equipment | 4 | 2 | 1 | 0 | 36 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Current assets | 2,217 | 2,092 | 1,629 | 2,338 | 1,547 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Current liabilities | 393 | 370 | 539 | 493 | 375 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Short-term borrowings | 183 | 184 | 291 | 282 | 87 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Bonds | — | — | — | — | 175 | S100XUJT |
| Total liabilities | 446 | 425 | 594 | 549 | 605 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Equity attributable to owners of parent | 1,858 | 1,777 | 1,140 | 1,910 | 1,107 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Retained earnings | -2,774 | -4,016 | -5,236 | -1,021 | -2,004 | S100QGF6, S100USPT, S100VI6N, S100XUJT |
| Treasury stock | -0 | -0 | -0 | -0 | -0 | S100QGF6, S100USPT, S100VI6N, S100XUJT |

### Assets and funding mix

| Assets | Share | Source |
| --- | ---: | ---: |
| Cash | 70% | S100XUJT |
| Inventories | 3% | S100XUJT |
| Property, plant and equipment | 2% | S100XUJT |
| Other assets | 25% | S100XUJT |

| Funding source | Share | Source |
| --- | ---: | ---: |
| Other liabilities | 35% | S100XUJT |
| Equity | 65% | S100XUJT |

### Balance sheet history

| Metric | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Total assets | 2,339 | 2,215 | 1,751 | 2,469 | 1,728 |
| Equity | 1,893 | 1,791 | 1,158 | 1,920 | 1,122 |
| Interest-bearing debt | — | — | — | — | — |
| Cash | 1,791 | 1,727 | 1,326 | 2,063 | 1,205 |

## Asset intensity and goodwill

Ratios are derived from reported values. Goodwill is used only when separately reported, never inferred from combined intangible assets.

| Metric | Value | Sources |
| --- | ---: | ---: |
| Asset intensity (fixed assets ÷ revenue) | 6.1% | S100XUJT |
| Fixed assets ÷ total assets | 2.1% | S100XUJT |
| Goodwill ÷ parent equity | — | —, S100XUJT |

### Cash quality

Net cash = cash − interest-bearing debt. Net debt ratio = (interest-bearing debt − cash) ÷ positive operating cash flow. Omit when debt components are incomplete; other ratios are derived from reported figures.

| Metric | Value |
| --- | ---: |
| Cash ratio (cash ÷ total assets) | 69.8% |
| Cash ÷ revenue | 203.1% |
| Net cash (cash − interest-bearing debt) | — |
| Net debt ÷ operating cash flow | — |
| Cash conversion (operating CF ÷ operating income) | — |
| Cash vs. profit gap | 47 JPY mn |
| Shareholder returns / net income | — |
| Shareholder returns / FCF | — |
| Shareholder payments — dividends / net income | — |
| Shareholder payments — dividends / FCF | — |
| CapEx intensity (capex ÷ revenue) | 6.8% |
| Investing CF relative to operating CF | — |

## ROA and ROE

ROE is decomposed into net margin × asset turnover × financial leverage. Leverage can raise ROE, so the ratio alone does not assess a company's condition. Ending balances are used without a prior year; total equity approximates parent equity when unavailable.

| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE | Sources |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| 2021 | — | —× | -63.3% | —× | — | S100QGF6 |
| 2022 | — | —× | -54.6% | —× | — | S100USPT |
| 2023 | — | —× | -61.5% | —× | — | S100VI6N |
| 2024 | — | —× | -48.4% | —× | — | S100XUJT |
| 2025 | — | —× | -46.8% | —× | — | S100XUJT |

## Ownership

| Counterparty | Relation | Ratio | As of |
| --- | ---: | ---: | ---: |
| 渡邊 賢二 | Major shareholder | 3.1% | 2025-12-31 |
| 太田 邦史 | Major shareholder | 1.4% | 2025-12-31 |
| 江平 文茂 | Major shareholder | 1.4% | 2025-12-31 |
| 楽天証券株式会社共有口 | Major shareholder | 1.4% | 2025-12-31 |
| 平田 重一 | Major shareholder | 1.1% | 2025-12-31 |
| 日本証券金融株式会社 | Major shareholder | 1.0% | 2025-12-31 |
| 御所野 侃 | Major shareholder | 1.0% | 2025-12-31 |
| 飯作 哲男 | Major shareholder | 0.9% | 2025-12-31 |
| 巻幡 俊 | Major shareholder | 0.8% | 2025-12-31 |
| 山戸 福太郎 | Major shareholder | 0.8% | 2025-12-31 |

## Sources

| Document | ID | Published | URL |
| --- | ---: | ---: | ---: |
| 有価証券報告書－第22期(2025/01/01－2025/12/31) | S100XUJT | 2026-03-27 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100XUJT,, |
| 有価証券報告書－第21期(2024/01/01－2024/12/31) | S100VI6N | 2025-03-28 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100VI6N,, |
| 訂正有価証券報告書－第20期(2023/01/01－2023/12/31) | S100USPT | 2024-11-15 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100USPT,, |
| 有価証券報告書－第19期(2022/01/01－2022/12/31) | S100QGF6 | 2023-03-28 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100QGF6,, |
| 有価証券報告書－第18期(令和3年1月1日－令和3年12月31日) | S100NQ6T | 2022-03-25 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100NQ6T,, |
| 有価証券報告書－第17期(令和2年1月1日－令和2年12月31日) | S100L137 | 2021-03-26 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100L137,, |

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).